Medicine-Serialisation Board Examiner — Specialty Pharmaceuticals

The mandate

The board repeatedly asks whether serialisation investment protects authentic product flow or has become a growing estate of local exceptions repaired by packaging and distribution specialists. Management reports successful code generation and repository availability, but directors cannot see aggregation breaks, rework, partner latency, suspect-product handling and market-specific release consequences across outsourced manufacturing and logistics.

Each month reserves two days for chair preparation, partner and management challenge and one major market or platform paper; five committee meetings are included across the engagement. A material traceability incident receives written observations within one Swiss business day. Batch investigation, Quality release or supplier selection demands a new written commission with its own safeguards.

The fixed term lasts ten months from January 2027 and concludes after the tenth monthly cycle. During month eight, directors will test whether management can apply the serialisation evidence framework independently across upcoming launches. A four-month renewal needs full-board approval and a named regulatory transition; executives cannot prolong access, bank unused days or convert challenge into operational issue resolution.

This examiner has no line authority, executive responsibility, Qualified Person delegation, product-release sign-off, regulatory representation or procurement vote. Advice challenges evidence and economics but cannot disposition a batch or suspect pack. Accountable Quality, Supply and market teams retain every decision, and the appointment cannot be represented as independent validation of compliance.

Up to two other material appointments are allowed with disclosure of work for pharmaceutical companies, contract manufacturers, repository operators, packaging vendors, distributors and assurance firms. Compensation from an active supplier may require recusal. Access to another manufacturer’s incident, exception rates or contract terms cannot be reused as anonymised comparison without permission.

Why the board wants this voice

Directors understand pharmaceutical quality and supply but lack someone who has run serialisation across packaging, repository and dispenser boundaries. Technology teams emphasise message success while sites absorb rework. The board wants an operator who can expose exception economics and patient-supply risk without becoming a substitute Quality officer or platform seller.

What you will own

• Press directors to trace serial creation, commissioning, aggregation, shipment, verification, dispense, return and decommission through each market journey.
• Test evidence for packaging rework, aggregation break, partner rejection, repository delay and suspect-product escalation at effective time.
• Challenge service measures that hide manual correction, batch hold, relabelling, partner support and market-release consequence.
• Shape investment gates around exception prevention, recovery time, partner adoption, product availability and sustainable lifecycle cost.
• Probe concentration and exit risk across repositories, line systems, code providers, contract packers and distribution partners.
• Frame board scenarios involving recalled batch, reused identifier, partial aggregation, market outage and disputed suspect product.
• Coach the committee to separate technical trace, Quality disposition, regulatory duty and commercial supply decision.

Candidate qualifications

• Led production medicine serialisation or pharmaceutical traceability across multiple regulated markets, packaging sites and external supply partners.
• Governed pack, case and pallet aggregation through line rework, return, recall and national market-repository interaction.
• Changed an investment or supplier decision after exposing exception labour, product hold, relabelling or partner-failure economics.
• Managed suspect-product and traceability incidents while preserving Qualified Person, manufacturer and market-authority decisions.
• Presented serialisation control evidence to pharmaceutical boards or regulators without overstating technical message success as compliance.
• Managed disclosed conflicts across manufacturers, contract packers, repositories, distributors, platform vendors and assurance providers.

Non-negotiables

• Able to attend all five Zurich meetings and preserve two advisory days monthly for the ten-month term.
• Will disclose pharmaceutical, packaging, repository, distribution and assurance interests before receiving incident evidence.
• Accepts that batch, Quality, regulatory and product-supply decisions remain with authorised client functions.
• Must bring production serialisation experience; generic supply traceability or ERP leadership is insufficient.

1. 49 words maximum. Describe a serialisation exception whose real consequence appeared in packaging rework or product release, not message uptime.
2. 49 words maximum. Which current manufacturer, packer, repository or vendor interests require board disclosure?
3. 49 words maximum. How would you test aggregation integrity after a partially reworked pharmaceutical batch?